Neon Therapeutics, Inc. Common Stock
NTGN
NTGN was delisted on the 5th of May, 2020.
46 hedge funds and large institutions have $18.6M invested in Neon Therapeutics, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 17 increasing their positions, 17 reducing their positions, and 13 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 17
21% less funds holding
Funds holding: 58 → 46 (-12)
34% less capital invested
Capital invested by funds: $28.4M → $18.6M (-$9.74M)
92% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$432K |
| 2 |
Millennium Management
New York
|
+$225K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$82K |
| 4 |
FIA
FNY Investment Advisers
New York
|
+$63.9K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$52.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$770K |
| 2 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$332K |
| 3 |
MA
MYDA Advisors
Woodmere,
New York
|
-$267K |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$104K |
| 5 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$103K |
NTGN Hedge Fund Activity: Q4 2019 in Review
46 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Neon Therapeutics, Inc. Common Stock (NTGN) for Q4 2019, worth a combined $18.6M — down 34% from $28.4M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of NTGN and 1 opened new positions — a net loss of 12 holders — while 17 trimmed existing stakes and 17 added.
The largest buyer was Anson Funds Management, opening a new position worth an estimated $432K. The largest seller was Fidelity Investments, cutting an estimated $770K.
- 46 institutional investors held Neon Therapeutics, Inc. Common Stock (NTGN) as of Q4 2019, down from 58 in Q3 2019.
- Funds reported $18.6M of Neon Therapeutics, Inc. Common Stock stock for Q4 2019, down 34% quarter-over-quarter.
- 1 fund opened new Neon Therapeutics, Inc. Common Stock positions in Q4 2019 and 13 closed out, a net change of -12 holders.
- The largest Neon Therapeutics, Inc. Common Stock buyer in Q4 2019 was Anson Funds Management, an estimated $432K added.
- The largest Neon Therapeutics, Inc. Common Stock seller in Q4 2019 was Fidelity Investments, an estimated $770K sold.
Based on aggregated 13F filings for Q4 2019.